2455 related articles for article (PubMed ID: 25468140)
21. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
22. Molecular predictors of response to therapy for breast cancer.
Galanina N; Bossuyt V; Harris LN
Cancer J; 2011; 17(2):96-103. PubMed ID: 21427553
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
24. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
Li T; Kung HJ; Mack PC; Gandara DR
J Clin Oncol; 2013 Mar; 31(8):1039-49. PubMed ID: 23401433
[TBL] [Abstract][Full Text] [Related]
25. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
26. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
Koch C; Trojan J
Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
[TBL] [Abstract][Full Text] [Related]
27. Personalized therapy for breast cancer.
De Abreu FB; Schwartz GN; Wells WA; Tsongalis GJ
Clin Genet; 2014 Jul; 86(1):62-7. PubMed ID: 24635704
[TBL] [Abstract][Full Text] [Related]
28. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
[TBL] [Abstract][Full Text] [Related]
29. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
Andorfer CA; Necela BM; Thompson EA; Perez EA
Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
[TBL] [Abstract][Full Text] [Related]
31. Companion biomarkers: paving the pathway to personalized treatment for cancer.
Duffy MJ; Crown J
Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
[TBL] [Abstract][Full Text] [Related]
32. Rare mutations in non-small-cell lung cancer.
D'Arcangelo M; D'Incecco A; Cappuzzo F
Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
34. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapy in Brain Metastases: Ready for Primetime?
Venur VA; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e123-30. PubMed ID: 27249714
[TBL] [Abstract][Full Text] [Related]
36. Personalized medicine: present and future of breast cancer management.
Sabatier R; Gonçalves A; Bertucci F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
[TBL] [Abstract][Full Text] [Related]
37. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
38. Gender-associated expression of tumor markers and a small gene set in breast carcinoma.
Andres SA; Smolenkova IA; Wittliff JL
Breast; 2014 Jun; 23(3):226-33. PubMed ID: 24656773
[TBL] [Abstract][Full Text] [Related]
39. Overcoming Resistance to Targeted Therapies in Cancer.
Redmond KL; Papafili A; Lawler M; Van Schaeybroeck S
Semin Oncol; 2015 Dec; 42(6):896-908. PubMed ID: 26615134
[TBL] [Abstract][Full Text] [Related]
40. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.
Schink JC; Trosman JR; Weldon CB; Siziopikou KP; Tsongalis GJ; Rademaker AW; Patel JD; Benson AB; Perez EA; Gradishar WJ
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
